The psychobiology of resilience and vulnerability to anxiety disorders: Implications for prevention and treatment

Dialogues in Clinical Neuroscience

Volumn 5, Issue 3, 2003, Pages 207-221

  Charney, Dennis S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anxiety disorder; Fear; Neurochemistry; Psychobiology; Resilience

Indexed keywords

BENZODIAZEPINE; CORTICOTROPIN RELEASING FACTOR; ESTROGEN; GALANIN; HYDROCORTISONE; NEUROPEPTIDE Y; NORADRENALIN; PRASTERONE; SEROTONIN; TESTOSTERONE;

ANXIETY; ANXIETY DISORDER; CONDITIONING; DISEASE PREDISPOSITION; FEAR; HUMAN; MENTAL STRESS; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PSYCHOBIOLOGY; REINFORCEMENT; REVIEW; REWARD; RISK FACTOR; SOCIAL BEHAVIOR;

EID: 0344873697     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Charney DS, Barlow DH, Botteron K, et al. Neuroscience research agenda to guide development of a pathophysiologically based classification system. In: Kupfer DJ, First MB, Reiger DA, eds. A Research Agenda for DSM-V. Washington, DC: American Psychiatric Association; 2002:31-83.
2. Charney DS. Psychobiological mechanisms of resilience and vulnerability: Implications for the successful adaptation to extreme stress. Am J Psychiatry. 2003. In press.
3. Richardson GE. The metatheory of resilience and resiliency. J Clin Psychol. 2002;58:307-321.
4. Masten AS, Coatsworth JD. The development of competence in favorable and unfavorable environments. Am Psychologist. 1998;53:205-220.
5. Bell CC. Cultivating resiliency in youth. J Adolesc Health. 2001;29:375-381.
6. Grinker R, Spiegel J. Men under Stress. Philadelphia, Pa: Churchills; 1945.
7. Rachman SJ. Fear and Courage. 2nd ed. New York, NY: Freeman and Company; 1992.
8. Ruff G, Korchin S. Psychological responses of the Mercury astronauts to stress. In: Grosser G, Wechsler H, Greenblatt M, eds. The Threat of Impending Disaster. Cambridge, Mass: MIT Press; 1964.
9. Keogh E, Dilon C, Georgiou G, Hunt C. Selective attentional biases for physical threat in physical anxiety sensitivity. J Anxiety Disord. 2001;15:299-315.
10. McNally RJ. Anxiety sensitivity and panic disorder. Biol Psychiatry. 2002;52:938-946.
11. Rapee RM. The development and modification of temperamental risk for anxiety disorders: prevention of a lifetime of anxiety? Biol Psychiatry. 2002;52:947-957.
12. Prior M, Smart D, Sanson A, Oberkiaid F. Does shy-inhibited temperament in childhood lead to anxiety problems in adolescence? J Am Acad Child Adolesc Psychiatry. 2000;39:461-468.
13. Vasey MW, Dadds MR. The Developmental Psychopathology of Anxiety. New York, NY: Oxford University Press; 2001.
14. Kagan J, Snidman N. Early childhood predictors of adult anxiety disorders. Biol Psychiatry. 1999;46:1536-1541.
15. Kagan J, Snidman N, Arcus D. Childhood derivatives of high and low reactivity in infancy. Child Dev. 1998;69:1483-1493.
16. Kagan J, Reznick JS, Snidman N. Biological bases of childhood shyness. Science. 1998;240:167-171.
17. Kagan J, Snidman N, Zentner M, Peterson E. Infance temperament and anxious symptoms in school age children. Dev Psychopathol. 1999;11:209-224.
18. Schwartz CE, Snidman N, Kagan J. Adolescent social anxiety as an outcome of inhibited temperament in childhood. J Am Acad Chld Adolesc Psychiatry. 1999;38:1008-1015.
19. Biederman J, Hirshfeld-Bcker DR, Rosenbaum JF, et al. Further evidence of association between behavioral inhibition and social anxiety in children. Am J Psychiatry. 2001;158:1673-1679.
20. Hudson JL, Rapee RM. Parent-child interactions and anxiety disorders: an observational study. Behav Res Ther. 2001;12:1411-1427.
21. Schwartz CE, Wright CI, Shin LM, Kagan J, Rauch SL. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;300:1952-1953.
22. Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry. 2002;52:381-385.
23. Diamond DM, Fleshner M, Ingersoll N, Rose GM. Psychological stress impairs spatial working memory: relevance to electrophysiological studies of hippocampal function. Behav Neurosci. 1996;110:661-672.
24. Makino S, Gold PW, Schulkin J. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res. 1994;675:141-149.
25. Makino S, Gold PW, Schulkin J. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res. 1995;640:105-112.
26. Shepard JD, Barron KW, Myers DA. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res. 2000;861:288-295.
27. Lee Y, Schulkin, Davis M. Effect of corticosterone on the enhancement of the acoustic startle reflex by corticotropin-releasing factor (CRF). Brain Res. 1994;666:93-98.
28. Roozendaal B. Glucocorticoids and the regulation of memory consolidation. Psychoeuroendocrinology. 2000;25:213-238.
29. Korte SM. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev. 2001;25:117-142.
30. Rosenfeld RS, Hellman L, Roffwarg H, Weitzman ED, Fukushima DK, Gallagher TF. Dehydroisoandrosterone is secreted episodically and synchronously with cortisol by normal man. J Clin Endocrinol. 1971;33:87-92.
31. Browne ES, Wright BE, Porter JR, Svec F. Dehydroepiandrosterone: antiglucocorticoid action in mice. Am J Med Sci. 1992;303:366-371.
32. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci U S A. 1998;95:1852-1857.
33. Bastianetto S, Ramassamy C, Poirier J, LQuirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Mol Brain Res. 1999;66:35-41.
34. Kaminska M, Harris J, Gilsbers K, Dubrovsky B. Dehydroepiandroserone sulfate (DHEAS) counteracts decremental effects of corticosterone on dentate gyrus LTR Implications for depression. Brain Res Bull. 2000;52:229-234.
35. Morgan CA. Predicting performance: what we can learn from psychobiological studies of humans participating in highly stressful military training. Annual Meeting of the Society for Biological Psychiatry, New Orleans, LA, May 2001.
36. Goodyer IM, Herbert J, Altham PME. Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med. 1998;28:265-273.
37. Goodyer IM, Park RJ, Netherton CM, Herberg J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatry. 2001;179:243-249.
38. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002;159:1237-1239.
39. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646-649.
40. A receptor. Mechanism of action and physiological significance. Prog Neurobiol. 1992;38:379-395.
41. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated by sigma receptors. J Neurosci. 1996;16:1193-1202.
42. Grammatopoulos DK, Chrousos GP. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab. 2002;13:436-444.
43. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry. 1999;46:1480-1508.
44. Strome EM, Trevor GHW, Higley JD, Liriaux DL, Suomi SJ, Doudet DJ. Intracerebroventricular corticotropin-releasing factor increased limbic glucose metabolism and has social context dependent behavioral effects in nonhuman primates. Proc Natl Acad Sci U S A. 2002;99:15749-15754.
45. Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, Holsboer F, Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology. 2000;39:1474-1481.
46. Bale TL, Vale WW. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J Neurosci. 2003;12:5295-5301.
47. Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 1997;154:624-629.
48. Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999;156:585-588.
49. Bremner JD, Krystal JH, Southwick SM. Noradrenergic mechanisms in stress and anxiety I. Preclinical studies. Synapse. 1996;23:28-38.
50. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987;144:1030-1036.
51. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand. 1992;86:273-282.
52. Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158:1227-1230.
53. Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 1997;54:749-758.
54. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002;5:189-192.
55. Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J Trauma Stress. 2002;15:433-437.
56. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry. 2002;63:S65-568.
57. Makino S, Baker RA, Smith MA, Gold PW. Differential regulation of neuropeptide Y mRNA expression in the accurate nucleus and locus coeruleus by stress and antidepressants. J Neuroendocrinol. 2000;12:387-395.
58. Baker RA, Herkenham M. Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. J Comp Neurol. 1995;358:518-530.
59. Risold PY, Swanson LW. Chemoarchitecture of the rat lateral septal nucleus. Brain Res Rev. 1997:24.
60. Pieribone VA, Brodin L, Friberg K, et al. Differential expression of mRNAs for neuropeptide Y-related peptides in rat nervous tissues: possible evolutionary conservation. J Neurosci. 1992;12:3361-3371.
61. Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in the rat brain. Science. 1983;221:877-879.
62. Heilig M, McLeod S, Brot M, et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology. 1993;8:357-363.
63. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept. 1995;59:201-205.
64. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol. 1999;368:143-147.
65. Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport. 1999;10:3003-3007.
66. Flood JF, Baker ML, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res. 1989;503:73-82.
67. Illes P, Finta EP, Nieber K. Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurons. Naunyn Schmiedebergs Arch Pharmacol. 1993;348:546-548.
68. Thorsell A, Michalkiewicz M, Dumont Y, et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci U S A. 2000;97:12852-12857.
69. Britton KT, Akwa Y, Spina MG, Koob GP. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides. 2000;21:37-44.
70. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 1994;17:80-85.
71. Kask A, Rago L, Harro J. Alpha-helical CRF(9-41) prevents anxiogenic-like effect on NPY Y1 receptor antagonist BIBP3226 in rats. Neuroreport. 1997;8:3645-3647.
72. Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quiron R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Behav Rev. 2002;26:259-283.
73. Smagin GN, Harris RB, Ryan DH. Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci Lett. 1996;220:167-170.
74. Kask A, Rago L, Harro J. Naxiolytic-like effect of neuropeptide Y (NPY) and NPY 13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res. 1998;788:345-348.
75. Sheriff S, Dautzenberg FM, Mulchahey JJ, et al. Interaction of neuropeptide Y and corticotropin-releasing factor signaling pathways in AR-5 amygdalar cells. Peptides. 2001;22:2083-2089.
76. Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res. 1999;100:207-215.
77. Kask A, Rago L, Harro J. NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. Neuroreport. 1998;8:2713-2716.
78. Martins AP, Maras RA, Guimaraes FS. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray. Depress Anxiety. 2001;12:99-101.
79. Morgan CA, Wang S, Mason J, et al. Hormone profiles in humans experiencing military survival training. Biol Psychiatry. 2000;47:891-901.
80. Rasmusson AM, Hauger RI, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry. 2000;47:526-539.
81. Mathe AA. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology. 2002;27:756-764.
82. Holmes A, Yang RJ, Crawley JN. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J Mol Neurosci. 2002;18:151-165.
83. Bing O, Moller C, Engel JA, Soderpal B, Heilig M. Anxiolytic-like action of centrally administered galanin. Neurosci Lett. 1993;164:17-20.
84. Moller C, Sommer W, Thorsell A, Heilig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology. 1999;21:507-512.
85. Holmes A, Kinney JW, Wrenn CC, et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology. 2003;28:1031-1044.
86. Gentleman SM, Falkai P, Bogerts B, Herrero MT, Polak JM, Roberts GW. Distribution of galanin-like immunoreactivity in the human brain. Brain Res. 1989;505:311-315.
87. Perez SE, Wynic D, Steiner RA, Mufson EJ. Distribution of galaninergic immunoreactivity in the brain of the mouse. J Comp Neurol. 2001;434:158-185.
88. Sevcik J, Finta EP, Illes P. Galanin receptors inhibit the spontaneous firing of locus coeruleus neurons and interact with mu-opioid receptors. Eur J Pharmacol. 1993;230:223-230.
89. Xu ZQ, Tong YG, Hokfelt T. Galanin enhances noradrenaline-induced outward current on locus coeruleus noradrenergic neurons. Neuroreport. 2001;12:1179-1182.
90. Hokfelt T, Millhorn D, Seroogy K, et al. Coexistence of peptides with classical transmitters. Experientia. 1987;43:768-780.
91. Consolo S, Baldi G, Russi G, Civenni G, Bartfai T, Vezzani A. Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. Proc Natl Acad Sci U S A. 1994;91:8047-8051.
92. Heisler L, Chu HM, Brennan T, et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A. 1998;95:15049-15054.
93. Parks C, Robinson P, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin 1A receptor. Proc Natl Acad Sci U S A. 1998;95:10734-10739.
94. Gross C, Zhuang X, Stark K, et al. Serotonin 1A receptor acts during development to establish normal anxiety-like behavior in the adult. Nature. 2002;416:396-400.
95. Drevets WC, Frank JC, Kupfer DJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375-1387.
96. Gingrich JA. Mutational analysis of the serotonergic system: recent findings using knockout mice. Curr Drug Target CNS Neurol Disord. 2002;1:449-465.
97. Holmes A, Yang RJ, Murphy DL, Crawley JN. Evaluation of antidepressant-related behavioral response in mice lacking the serotonin transporter. Neuropsychopharmacology. 2002;27:914-923.
98. Caspi A, Sugden K, Moffit TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
99. Weizman R, Weizman A, Kook KA, Vocci F, Deutsch S, Paul SM. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther. 1989;249:701-707.
100. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-396.
101. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715-720.
102. Bremner JD, Innis RB, White T, et al. SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96-106.
103. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry. 2000;157:1120-1126.
104. Zitzmann M, Nieschlag E. Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs. Eur J Endocrinol. 2001;144:183-187.
105. Lee S, Miselis R, Rivier C. Anatomical and functional evidence for a neural hypothalamic-testicular pathway that is independent of the pituitary. Endocrinology. 2002;143:4447-4454.
106. Mulchahey JJ, Ekhator NN, Zhang H, Kasckow JW, Baker DG, Geracioti TD Jr. Cerebrospinal fluid and plasma testosterone levels in post-traumatic stress disorder and tobacco dependence. Psychoneuroendocrinology. 2001;26:273-285.
107. Stroud LR, Salovey P, Epel ES. Sex differences in stress responses: social rejection versus achievement stress. Biol Psychiatry. 2002;52:318-327.
108. Young EA, Altemus M, Parkison V, Shastry S. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. Neuropsychopharmacology. 2001;25:881-891.
109. Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab. 1999;84:606-610.
110. Cucinelli F, Soranna L, Barini A, et al. Estrogen treatment and body fat distribution are involved in corticotropin and cortisol response to corticotropin-releasing hormone in postmenopausal women. Metab Clin Exp. 2002;51:137-143.
111. Young EA. Sex differences in response to exogenous corticosterone. Mol Psychiatry. 1996;1:313-319.
112. Yonkers KA, Ellison JM. Anxiety disorders in women and their pharmacological treatment. In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women. Washington, DC: American Psychiatric Press; 1996:261-285.
113. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
114. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002;36:229-240.
115. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet. 2002;114:391-406.
116. Blair HT, Schafe GE, Bauer EP, Rodrigues SM, LeDoux JE. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learning Memory. 2001;8:229-242.
117. Walker DL, Davis M. Involvement of NMDA receptors within the amygdala in short-versus long-term memory for fear conditioning as assessed with fear-potentiated startle. Behav Neurosci. 2000;114:1019-1033.
118. Rodrigues SM, Schafe GE, LeDoux JE. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J Neurosci. 2001;21:6889-6896.
119. Grillon C. Associative learning deficits increase symptoms of anxiety in humans. Biol Psychiatry. 2002;51:851-858.
120. Bauer EP, Schafe GE, LeDoux JE. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. J Neurosci. 2002;22:5239-5249.
121. McGaugh JL. Memory consolidation and the amygdala: a systems perspective. Trends Neurosci. 2002;25:456-461.
122. McIntyre CK, Hatfield T, McGaugh JL. Amygdala norepinephrine levels after training predict inhibitory avoidance retention performance in rats. Eur J Neurosci. 2002;16:1223-1226.
123. Roozendaal B, Brunson KL, Holloway BL, McGaugh JL, Baram TZ. Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci U S A. 2002;99:13908-13913.
124. Debiec J, LeDoux JE, Nader K. Cellular and systems reconsolidation in the hippocampus. Neuron. 2002;36:527-538.
125. Milekic MH, Alberini CM. Temporally graded requirement for protein synthesis following memory reactivation. Neuron. 2002;36:521-525.
126. Myers KM, Davis M. Systems-level reconsolidation: re-engagement of the hippocampus with memory reactivation. Neuron. 2002;36:340-343.
127. Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: role of β-adrenergic receptors. J Neurosci. 1999;19:6623-6628.
128. Sara SJ. Retrieval and reconsolidation: toward a neurobiology of remembering. Learning Memory. 2000;7:73-84.
129. Nader K, Schafe GE, LeDoux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406:722-726.
130. Kida S, Josselyn SA, de Ortiz SP, et al. CREB required for the stability of new and reactivated fear memories. Nat Neurosci. 2002;4:348-355.
131. Przybyslawski J, Sara SJ. Reconsolidation of memory after its reactivation. Behav Brain Res. 1997;84:241-246.
132. Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventral medial prefrontal cortex in the recovery of extinguished fear. J Neurosci. 2000;20:6225-6231.
133. Morgan MA, Romanski LM, LeDoux JE. Extinction of emotional learning: contribution of medial prefrontal cortex. Neurosci Lett. 1993;163:109-113.
134. Herry C, Garcia R. Prefrontal cortex long-term potentiation but not long-term depression is associated with maintenance of extinction of learned fear in mice. J Neurosci. 2002;22:577-583.
135. Bremner JD, Staib LH, Kaloupek D, Southwick SM, Soufer R, Charney DS. Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. Biol Psychiatry. 1999;45:806-816.
136. Davis M. The role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur J Neurosci. 2002;16:395-398.
137. Young LJ. The neurobiology of social recognition, approach and avoidance. Biol Psychiatry, 2002;51:18-26.
138. Insel TR, Wang Z, Ferris CF. Patterns of brain vasopressin receptor distribution associated with social organization in microtine rodents. J Neurosci. 1994;14:5381-5392.
139. Young LJ, Winslow JT, Nilsen R, Insel TR. Species differences in V1a receptor gene expression in monogamous and non-monogamous voles: behavioral consequences. Behav Neurosci. 1997;111:599-605.
140. DeRijk RH, Schaaf M, de Kloet ER. Glucocorticoid receptor variants: clinical implications. Steroid Biochem Mol Biol. 2002;81:103-122.
141. 2c adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135-1142.
142. Kallio J, Personen U, Kaipio K, et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in man. FASEB J. 2001;15:1242-1244.
143. Shumyatsky G, Tsvetkov, E, Malleret G, et al. Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear. Cell. 2002;111:905-918.
144. Goddard AW, Mason GF, Rothman DL, et al. Reductions in occipital cortex GABA levels in panic disorder. Arch Gen Psychiatry. 2001;58:556-561.
145. Hettema JM, Annas P, Neale MC, Kendler KS, Fredrikson M. A twin study of the genetics of fear conditioning. Arch Gen Psychiatry. 2003;60:702-708.
146. Insel TR, Young U. The neurobiology of attachment. Nat Rev Neurosci. 2001:129-136.
147. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400-403.